88 related articles for article (PubMed ID: 22040998)
1. [Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].
Chen YX; Li Y; Zhang LY; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1329-33. PubMed ID: 22040998
[TBL] [Abstract][Full Text] [Related]
2. Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.
Dunbar AJ; Bowman RL; Park YC; O'Connor K; Izzo F; Myers RM; Karzai A; Zaroogian Z; Kim WJ; Fernández-Maestre I; Waarts MR; Nazir A; Xiao W; Codilupi T; Brodsky M; Farina M; Cai L; Cai SF; Wang B; An W; Yang JL; Mowla S; Eisman SE; Hanasoge Somasundara AV; Glass JL; Mishra T; Houston R; Guzzardi E; Martinez Benitez AR; Viny AD; Koche RP; Meyer SC; Landau DA; Levine RL
Cancer Discov; 2024 May; 14(5):737-751. PubMed ID: 38230747
[TBL] [Abstract][Full Text] [Related]
3. Effect of hypoxia on HIF-1α and NOS3 expressions in CD34
Şoroğlu CV; Uslu-Bıçak İ; Toprak SF; Yavuz AS; Sözer S
Adv Med Sci; 2023 Sep; 68(2):169-175. PubMed ID: 37075583
[TBL] [Abstract][Full Text] [Related]
4. Platelets and neutrophils cooperate to induce increased neutrophil extracellular trap formation in JAK2V617F myeloproliferative neoplasms.
Guy A; Garcia G; Gourdou-Latyszenok V; Wolff-Trombini L; Josserand L; Kimmerlin Q; Favre S; Kilani B; Marty C; Boulaftali Y; Labrouche-Colomer S; Mansier O; James C
J Thromb Haemost; 2024 Jan; 22(1):172-187. PubMed ID: 37678548
[TBL] [Abstract][Full Text] [Related]
5. Jmjd1c is dispensable for healthy adult hematopoiesis and Jak2V617F-driven myeloproliferative disease initiation in mice.
Staehle HF; Heinemann J; Gruender A; Omlor AM; Pahl HL; Jutzi JS
PLoS One; 2020; 15(2):e0228362. PubMed ID: 32017785
[TBL] [Abstract][Full Text] [Related]
6. Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms.
Gou P; Liu D; Ganesan S; Lauret E; Maslah N; Parietti V; Zhang W; Meignin V; Kiladjian JJ; Cassinat B; Giraudier S
Blood Cancer J; 2024 Jan; 14(1):1. PubMed ID: 38177095
[TBL] [Abstract][Full Text] [Related]
7. Gadd45g insufficiency drives the pathogenesis of myeloproliferative neoplasms.
Zhang P; You N; Ding Y; Zhu W; Wang N; Xie Y; Huang W; Ren Q; Qin T; Fu R; Zhang L; Xiao Z; Cheng T; Ma X
Nat Commun; 2024 Apr; 15(1):2989. PubMed ID: 38582902
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Molecular Response in Myeloproliferative Neoplasms with Complete JAK2V617F Inhibition.
Celik H; Challen GA
Cancer Discov; 2024 May; 14(5):701-703. PubMed ID: 38690601
[TBL] [Abstract][Full Text] [Related]
9. The
Orbell LY; Abutheraa N; Duncombe AS; McMullin MF; Mesa R; McShane CM; James G; Anderson LA
EJHaem; 2023 Nov; 4(4):1071-1080. PubMed ID: 38024634
[TBL] [Abstract][Full Text] [Related]
10. PCM1::JAK2 myeloproliferative neoplasm suggested by bone marrow histopathological features.
Loscocco GG; Santi R
Blood; 2024 Jun; 143(23):2439. PubMed ID: 38842862
[No Abstract] [Full Text] [Related]
11. Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells.
Bao EL; Nandakumar SK; Liao X; Bick AG; Karjalainen J; Tabaka M; Gan OI; Havulinna AS; Kiiskinen TTJ; Lareau CA; de Lapuente Portilla AL; Li B; Emdin C; Codd V; Nelson CP; Walker CJ; Churchhouse C; de la Chapelle A; Klein DE; Nilsson B; Wilson PWF; Cho K; Pyarajan S; Gaziano JM; Samani NJ; ; ; Regev A; Palotie A; Neale BM; Dick JE; Natarajan P; O'Donnell CJ; Daly MJ; Milyavsky M; Kathiresan S; Sankaran VG
Nature; 2020 Oct; 586(7831):769-775. PubMed ID: 33057200
[TBL] [Abstract][Full Text] [Related]
12. Adrenal infarction with latent myelodysplastic/myeloproliferative neoplasm, unclassifiable with
Yasuda S; Chiba M; Nishitani R; Watanabe T
Clin Case Rep; 2024 Apr; 12(4):e8729. PubMed ID: 38601172
[TBL] [Abstract][Full Text] [Related]
13. [Somatic JAK2 gene mutation is an evolving risk factor in cardiovascular diseases].
Magyar E; Újfalusi A; Czenke M; Méhes G
Orv Hetil; 2024 Jun; 165(23):883-890. PubMed ID: 38852144
[TBL] [Abstract][Full Text] [Related]
14.
Diz-Küçükkaya R; İyigün T; Albayrak Ö; Eker C; Günel T
Turk J Haematol; 2024 May; ():. PubMed ID: 38801025
[TBL] [Abstract][Full Text] [Related]
15. Quantitative interpretation of bone marrow biopsies in MPN-What's the point in a molecular age?
Ryou H; Lomas O; Theissen H; Thomas E; Rittscher J; Royston D
Br J Haematol; 2023 Nov; 203(4):523-535. PubMed ID: 37858962
[TBL] [Abstract][Full Text] [Related]
16. Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology.
Royston D; Mead AJ; Psaila B
Hematol Oncol Clin North Am; 2021 Apr; 35(2):279-293. PubMed ID: 33641869
[TBL] [Abstract][Full Text] [Related]
17. The Hen or the Egg: Inflammatory Aspects of Murine MPN Models.
Jutzi JS; Pahl HL
Mediators Inflamm; 2015; 2015():101987. PubMed ID: 26543325
[TBL] [Abstract][Full Text] [Related]
18. Relating NF-κB regulation to MPN pathogenesis.
Sullivan JY; Fleischman AG
Blood; 2024 Jun; 143(23):2345-2347. PubMed ID: 38842861
[No Abstract] [Full Text] [Related]
19. JAK2V617F and ischemic stroke: CHIP or CMD-NBV?
Barosi G; Rosti V; Gale RP
Blood Adv; 2023 Dec; 7(23):7329-7330. PubMed ID: 37956267
[No Abstract] [Full Text] [Related]
20. Soluble interleukin-6 receptor in patients with
Garbers C; Rose-John S
EClinicalMedicine; 2020 May; 22():100340. PubMed ID: 32395711
[No Abstract] [Full Text] [Related]
[Next] [New Search]
